ReviewKidney international reports2019
Strategies for Phosphate Control in Patients With CKD.
Review in Kidney international reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 3 syntheses or guidelines pooled it, 126 citations in OpenAlex.
- The efficacy and safety of cuttlebone for lowering serum phosphate in patients with end-stage renal disease: a meta-analysis of randomized controlled trials.Frontiers in pharmacology · 2023Pooled it
- Pooled it
- Benefits of resistant starch type 2 for patients with end-stage renal disease under maintenance hemodialysis: a systematic review and meta-analysis.International journal of medical sciences · 2021Pooled it
- Palopegteriparatide for adults with chronic hypoparathyroidism: skeletal dynamics through 3 years of the phase 2 PaTH forward trial.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2026Trial
- Safety and Phosphate-Binding Capacity of Oxylanthanum Carbonate in Healthy Volunteers.Clinical and translational science · 2025Trial
- Pharmacokinetics, Safety, and Tolerability of Tenapanor in Healthy Chinese and Caucasian Volunteers: A Randomized, Open-Label, Single-Center, Placebo-Controlled Phase 1 Study.International journal of clinical practice · 2024Trial
- Safety and Efficacy of Tenapanor for Long-term Serum Phosphate Control in Maintenance Dialysis: A 52-Week Randomized Phase 3 Trial (PHREEDOM).Kidney360 · 2021Trial
- Phosphate: An Anion Controlling Metabolic Functions.Nutrients · 2026Review
- Emerging treatments and current strategies for mineral, vascular, and bone disorders in chronic kidney disease.World journal of nephrology · 2026Review
- From Biomarkers to Biosensors: Transforming Comorbidity Management in Dialysis Care.Sensors (Basel, Switzerland) · 2026Review
- The Impact of Tenapanor on Serum Phosphate in Adult Dialysis Patients: A Narrative Review.Kidney medicine · 2026Review
- Phosphate and Inflammation in Health and Kidney Disease.International journal of molecular sciences · 2025Review
- Dietary management of patients with type 2 diabetes and chronic kidney disease: A comprehensive literature review.World journal of nephrology · 2025Review
- Soft tissue calcifications in chronic kidney disease-beyond the vasculature.Pflugers Archiv : European journal of physiology · 2025Review
- The Complexities and Challenges of Managing Genetic Causes of Hyperphosphataemia, a Case Report.Journal of paediatrics and child health · 2025Article
- Elevated phosphate levels in CKD - a direct threat for the heart.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025Review
- Balancing Stone Prevention and Kidney Function: A Therapeutic Dilemma.Journal of clinical medicine · 2025Review
- Tenapanor: A novel therapeutic agent for dialysis patients with hyperphosphatemia.Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy · 2025Review
- Eryptosis in renal anemia: mechanisms, clinical implications, and therapeutic targeting.Frontiers in pharmacology · 2025Review
- Intradialytic serum phosphate variations are associated with low PTH levels.Journal of nephrology · 2024Observational
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hyperphosphatemia is a common complication in patients with chronic kidney disease (CKD), particularly in those requiring renal replacement therapy. The importance of controlling serum phosphate has long been recognized based on observational epidemiological studies that linked increased phosphate levels to adverse outcomes and higher mortality risk. Experimental data further supported the role of phosphate in the development of bone and cardiovascular diseases. Recent advances in our understanding of the mechanisms involved in phosphate homeostasis have made it clear that the serum phosphate concentration depends on a complex interplay among the kidneys, intestinal tract, and bone, and is tightly regulated by a complex endocrine system. Moreover, the source of dietary phosphate and the use of phosphate-based additives in industrialized foods are additional factors that are of particular importance in CKD. Not surprisingly, the management of hyperphosphatemia is difficult, and, despite a multifaceted approach, it remains unsuccessful in many patients. An additional issue is the fact that the supposedly beneficial effect of phosphate lowering on hard clinical outcomes in interventional trials is a matter of ongoing debate. In this review, we discuss currently available treatment approaches for controlling hyperphosphatemia, including dietary phosphate restriction, reduction of intestinal phosphate absorption, phosphate removal by dialysis, and management of renal osteodystrophy, with particular focus on practical challenges and limitations, and on potential benefits and harms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.